Table 1.
Baseline characteristics, treatments, and frequency of AEs occurring after immunization with the COVID‐19 messenger RNA vaccine among adolescent patients with JIA treated with TNF inhibitors*
| Demographic and clinical characteristics (n = 21) | |
| Age, median (IQR) years | 17 (16–21) |
| Sex | |
| Male | 5 (24) |
| Female | 16 (76) |
| Polyarticular JIA | 8 (38) |
| Psoriatic JIA | 7 (33) |
| ERA | 6 (29) |
| Treatment (n = 21) | |
| TNF inhibitors | |
| Adalimumab | 10 (48) |
| Etanercept | 11 (52) |
| Other concurrent treatment, methotrexate | 15 (71) |
| Postvaccination AEs (n = 21 patients, n = 42 vaccine doses) | |
| Local | 31 (74) |
| Erythema | 21 (50) |
| Pain | 32 (76) |
| Swelling | 12 (29) |
| Systemic | 8 (19) |
| Headache | 7 (17) |
| Myalgias | 5 (12) |
| Fatigue | 6 (14) |
| Transient arthralgia | 5 (12) |
| Allergic reaction | 1 (2) |
| Exacerbation of JIA | 0 (0) |
| Serious AEs | 0 (0) |
*
Except where indicated otherwise, values are the number (%). AEs = adverse events; JIA = juvenile idiopathic arthritis; TNF = tumor necrosis factor; IQR = interquartile range; ERA = enthesitis‐related arthritis.